{"id":"chemotherapy-adc-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ADCs combine monoclonal antibodies with chemotherapy drugs linked by a cleavable linker. The antibody component binds to specific antigens on cancer cell surfaces, enabling selective delivery of the chemotherapy payload to tumor cells while minimizing systemic exposure. This targeted approach aims to improve efficacy and reduce off-target toxicity compared to conventional chemotherapy.","oneSentence":"An antibody-drug conjugate (ADC) regimen that delivers cytotoxic chemotherapy payloads to cancer cells via targeted antibody binding to tumor-associated antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:53.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication not specified in available information)"}]},"trialDetails":[{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06519370","phase":"PHASE3","title":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-08-09","conditions":"Triple Negative Breast Cancer","enrollment":350},{"nctId":"NCT07281209","phase":"PHASE2","title":"A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-12","conditions":"NSCLC","enrollment":40},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT04606914","phase":"PHASE2","title":"Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-05-27","conditions":"Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer","enrollment":70},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT06472752","phase":"","title":"Neoadjuvant Radiotherapy for High-risk UTUC","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-06-30","conditions":"Urothelial Carcinoma of the Renal Pelvis and Ureter","enrollment":40},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT06123494","phase":"PHASE3","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-09","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":360},{"nctId":"NCT06121557","phase":"PHASE1","title":"Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-11-01","conditions":"Breast Neoplasms","enrollment":24},{"nctId":"NCT03606174","phase":"PHASE2","title":"A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma","status":"TERMINATED","sponsor":"Mirati Therapeutics Inc.","startDate":"2018-09-11","conditions":"Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter","enrollment":260},{"nctId":"NCT05228249","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":""},{"nctId":"NCT05134519","phase":"PHASE2","title":"RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2021-11-26","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Chemotherapy/ADC Regimen","genericName":"Chemotherapy/ADC Regimen","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirvetuximab soravtansine (MIRV) is a small molecule used in chemotherapy regimens for various cancers, including ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and salivary gland carcinoma. It is administered in combination with carboplatin as a first-line treatment for patients with advanced-stage ovarian, fallopian tube, or primary peritoneal cancer who have received neoadjuvant chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}